Clene Inc

Research Clene Inc (CLNN) on Bullrun: market cap USD 56.74M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

Valuation Snapshot

latest market cap is USD 56.74M.

Five-year financial history

YearRevenueNet incomeFree cash flowGross marginDiluted EPSCashTotal debtEquity
FY2025USD 200.00K-USD 26.17M-USD 18.59M78.5%-4.37USD 5.19MUSD 17.79M-USD 17.59M
FY2024USD 342.00K-USD 39.40M-USD 21.34M79.5%n/aUSD 12.16MUSD 20.84M-USD 8.86M
FY2023USD 654.00K-USD 49.50M-USD 30.50M81.5%-9.69USD 28.82MUSD 32.16MUSD 13.39M
FY2022USD 473.00K-USD 29.92M-USD 44.19M94.5%n/aUSD 18.33MUSD 26.74MUSD 3.24M

Valuation history

YearSnapshot dateMarket capP/EDividend yieldAnnual dividend/share
20262026-08-25USD 56.74Mn/an/an/a
20252025-12-31USD 60.66Mn/an/an/a
20242024-12-31USD 42.96Mn/an/an/a
20232023-12-29USD 38.52Mn/an/an/a
20222022-12-30USD 73.82Mn/an/an/a
20212021-12-31USD 255.48Mn/an/an/a

About Clene Inc

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. The company's lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS;

Related stock research

Other Consumer Defensive stocks

Frequently asked questions

What is Clene Inc's market cap?

Clene Inc's market capitalization is USD 56.74M.

What does Clene Inc do?

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics.